Deep Learning for Biomedicine

Truyen Tran
Deakin University

Jakarta, July 2019

truyen.tran@deakin.edu.au
truyentrtran.github.io
@truyenoz
letdataspeak.blogspot.com
goo.gl/3jJ1O0
Agenda

Why bother?

The futurist

Vectors & Sets

Graphs

Sequences

Biomed structures
Recent AI/ML/KDD activities

Conference on Machine Learning for Healthcare (MLHC), 2019

ICML/IJCAI/AAAI (2019)
- Health Intelligence
- Workshop on Computational Biology
- Knowledge Discovery in Healthcare III: Towards Learning Healthcare Systems (KDH)

KDD/SDM/ICDM (2018-2019)
- Health Day at KDD’18
- epiDAMIK: Epidemiology meets Data Mining and Knowledge discovery
- 17th International Workshop on Data Mining in Bioinformatics
- Workshop on Data Mining in Bioinformatics (BIOKDD 2019)
- [DsHealth 2019] 2019 KDD workshop on Applied data science in Healthcare: bridging the gap between data and knowledge
Why now?

**High-impact & data-intensive.**
- Andrew Ng’s rule: impact on 100M+ people.
- Biomedicine is the only industry that will never shrink!

Ripe for innovations fuelled by deep learning techniques.
- Major recent advances and low hanging fruits are being picked.

Great challenges:
- High volume and high dimensional;
- Any modality: 2D-4D vision, time-series, 1D signals, sound, text, social network, graphs.
- Metric scale from nano-meter (atoms) to meters (human body and brain).
- Time scale from mini-seconds (ion channels) to 100 years.
- Complexity unimaginable (e.g., brain, DNA, cell networks).
- Great privacy concerns;

It is the right time to join force with biomedical scientists!
Human genome

3 billion base-pairs (characters), 20K genes, 98% non-coding regions

Any two random persons share 99.9% genome

The 0.1% difference is thought to account for all variations between us
- Appearance: Height (80% heritable), BMI, hair, skin colors
- IQ, education levels
- Genetic disorders such as cancers, bipolar, schizophrenia, autism, diabetes, etc.

Any two random persons share about 60% variations (SNV/SNP)

As we age, there are small mutations within our cells
The cell, nuclear DNA & MtDNA

Mitochondrial DNA ring

DNA double helix

Core histone dimers: 2 x H2A/H2B
2 x H3/H4

‘Beads on a string’ form of chromatin

Chromatin fiber of packed nucleosomes

Condensed chromatin

Cell

Mitochondrial DNA

Mitochondria

Cell

https://en.wikipedia.org/wiki/Mitochondrial_DNA

https://qph.ec.quoracdn.net/main-qimg-2c39fede406d71fb534bbae6cc9b8aad-c
Sequencing

The first step is to read (sequence) the DNA/MtDNA, and represent the information as string of characters (A,C,G,T) in computer.

The most popular technique these days read short sequences (hundreds of characters), and align.

Each position is read typically at least 30 times to get enough confidence → Huge storage!!!

String alignment is then the key to final sequence → Need super-computer to do this fast.

A DNA sequence is compared against the reference genome. Only the difference (0.1%) need to be stored.

- This does not usually apply for MtDNA, as each cell has as many as 500 MtDNAs, they are slightly different! More different as we age.

Source: https://www.genome.gov
The state of AI for drug design

This is not new. Since 1960s!

$500M - $2B


http://www.pharmexec.com/specialized-metrics-properly-assess-ai-pharma-startups
The three questions

**Given a molecule, is this drug?** Aka properties/targets/effects prediction.
- Druglikeness
- Targets it can modulate and how much
- Its dynamics/kinetics/effects if administered orally or via injection

**Given a target, what are molecules?**
- If the list of molecules is given, pick the good one. If evaluation is expensive, need to search, e.g., using BO.
- If no molecule is found, need to generate from scratch → generative models + BO, or RL.

**Given a molecular graph, what are the steps to make the molecule?**
- Synthetic tractability
- Reaction planning, or retrosynthesis
Sensing technologies and data

Raw signals are ideal candidates for deep learning

Speech & vision techniques can be applied with minimal changes

Electronic medical records (EMR)

Need to model the healthcare processes, which are interactions of:

- Disease progression
- Interventions & care processes
- Recording processes (Electronic Medical/Health Records)

Irregular timing, event-based, sequence of (interacting) sets

Multiple resolutions

Mixed modalities: biomarkers, code, text, social, wearables

Human-in-the-loop; negative/positive feedback

Source: medicalbillingcodings.org
“They should stop training radiologists now.”

Geoff Hinton (as of April 2017)

https://www.newyorker.com/magazine/2017/04/03/ai-versus-md
An art of modelling biomedicine: Analogy

Video as sequence of frame, but also a complex 3D graph of objects, actions and scenes
- → Protein, RNA

Question as sequence of words, but also a complex dependency graph of concepts
- → Protein, drug

Answer as facts (what and where) and deduced knowledge.
- → Affinity, binding sites, modulation effect

#Ref: Minh-Thao Le, Vuong Le, Truyen Tran, “Learning to Reason with Relational Video Representation for Question Answering”, *In preparation 2019.*
Agenda

Why bother?
Vectors & Sets
Sequences
The futurist
Graphs
“Diet networks” for GWAS


**GWAS = Genome Wide Association Study**

Diet Net uses a “hypernet” to generate the main net.

Features are embedded (not data instance).

Unsupervised autoencoder as regularizer.

Works well on country prediction on the 1000 Genomes Project dataset.

- But this is a relatively easy problem. PCA, even random subspace can do quite well!
DeepPatient: Representing medical records with Stacked Denoising Autoencoder

Use of feedforward nets: Tissue-regulated splicing code

Operation on Gen Set

DeepTRIAGE: Interpretable and Individualised Biomarker Scores using Attention Mechanism for the Classification of Breast Cancer Sub-types

Adham Beykikhoshk1*, Thomas P. Quinn1*, Samuel C. Lee1, Truyen Tran1, and Svetla Venkatesh1

1Centre for Pattern Recognition and Data Analytics, Deakin University, Geelong, Australia
* adham.beykikhoshk@deakin.edu.au; contacttomquinn@gmail.com

Abstract

Motivation: Breast cancer is a collection of multiple tissue pathologies, each with a distinct molecular signature that correlates with patient prognosis and response to therapy. Accurately differentiating between breast cancer sub-types is an important part of clinical decision-making. Already, this problem has been addressed using machine learning methods that separate tissue samples into distinct groups. However, there remains unexplained heterogeneity within the established sub-types that cannot be resolved by the commonly used classification algorithms. In this paper, we propose a novel deep learning architecture, called DeepTRIAGE (Deep learning for the TRIactable Individualised Analysis of Gene Expression), which not only classifies cancer sub-types with comparable accuracy, but simultaneously assigns each patient their own set of interpretable and individualised biomarker scores. These personalised scores describe how important each feature is in the classification of each patient, and can be analysed post-hoc to generate new hypotheses about intra-class heterogeneity.

Results: We apply the DeepTRIAGE framework to classify the gene expression signatures of luminal A and luminal B breast cancer sub-types, and illustrate the use for genes and gene set (i.e., GO and KEGG) features. Using DeepTRIAGE, we find that the GINS1 gene and the kinetochore organisation GO term are the most important features for luminal sub-type classification. Through classification, DeepTRIAGE simultaneously reveals heterogeneity within the luminal A biomarker scores that significantly associate with tumour stage, placing all luminal samples along a continuum of severity.

Availability and Implementation: The proposed model is implemented in Python using PyTorch framework. The analysis is done in Python and R. All methods and models are freely available from https://github.com/adhas/BiomarkerAttend.

Attention mechanism

http://distill.pub/2016/augmented-rnns/
Agenda

- Why bother?
- Vectors & Sets
- Sequences
- The futurist
- Graphs
Deep architectures for nanopore sequencing

Aimed at real time recognition

The setting is similar to speech recognition!

- The early days used HMMs. Now LSTMs.

We will briefly review the latest:

- **Chiron** (Teng et al., May 2018, UQ, Australia)

Other GRU/LSTM variants

- Nanonet (Oxford Nanopore Technologies, 2016)
- BasecRAWller (Stoiber & Brown, May 2017)
- **DeepNano** (Boza et al., June 2017, Comenius University in Bratislava, Slovakia)
Chiron

Identifying binding sites


http://www.nature.com/nbt/journal/v33/n8/full/nbt.3300.html
User of CNN+RNNs: DanQ

Multiple modalities

THE CHROMPUTER

Integrating multiple inputs (1D, 2D signals, sequence) to simultaneously predict multiple outputs

Chromatins

Source: https://simons.berkeley.edu/sites/default/files/docs/4575/2016-kundaje-simonsinstitute-deeplearning.pdf

https://qph.ec.quoracdn.net
More models/frameworks

DragoNN
DeepChrome
DeepSEA
Basset
DeepBound

http://kundajelab.github.io/dragonn
Agenda

Why bother?

Vectors & Sets

Sequences

The futurist

Graphs
Biology & pharmacy

Traditional techniques:

- Graph kernels (ML)
- Molecular fingerprints (Chemistry)

Modern techniques

- Molecule as graph: atoms as nodes, chemical bonds as edges

Chemistry

DFT = Density Functional Theory


• Molecular properties
• Chemical-chemical interaction
• Chemical reaction
• Synthesis planning

Figure 1: A sample reaction represented as a set of graph transformations from reactants (leftmost) to products (rightmost). Atoms are labeled with their type (Carbon, Oxygen,...) and their index (1, 2,...) in the molecular graph. The atom pairs that change connectivity and their new bonds (if existed) are highlighted in green. There are two bond changes in this case: 1) The double bond between O:1 and C:2 becomes single. 2) A new single bond between C:2 and C:10 is added.
From vector to graph with PAN: Personalized Annotation Networks

Predicting molecular bioactivities as querying a graph

Controller

Task/query → Bioactivities

Memory

Drug molecule


#Ref: Pham, Trang, Truyen Tran, and Svetha Venkatesh. "Graph Memory Networks for Molecular Activity Prediction." ICPR’18.
Multi-target binding for drug repurposing as graph multi-labeling

(a) A input graph with 4 nodes and 3 labels
(b) Input node update
(c) Label node update

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Metrics</th>
<th>Fingerprint SVM</th>
<th>Fingerprint HWN</th>
<th>SMILES GRU</th>
<th>WL+SVM</th>
<th>CLN</th>
<th>GAML</th>
</tr>
</thead>
<tbody>
<tr>
<td>9cancers</td>
<td>m-AUC</td>
<td>81.94</td>
<td>85.95</td>
<td>83.29</td>
<td>86.06</td>
<td>88.35</td>
<td>88.78</td>
</tr>
<tr>
<td></td>
<td>M-AUC</td>
<td>81.37</td>
<td>85.85</td>
<td>82.74</td>
<td>85.74</td>
<td>88.23</td>
<td>88.50</td>
</tr>
<tr>
<td></td>
<td>m-F1</td>
<td>50.63</td>
<td>57.44</td>
<td>55.97</td>
<td>54.55</td>
<td>59.48</td>
<td>62.03*</td>
</tr>
<tr>
<td></td>
<td>M-F1</td>
<td>50.71</td>
<td>57.29</td>
<td>55.99</td>
<td>54.54</td>
<td>59.50</td>
<td>62.14*</td>
</tr>
<tr>
<td>50proteins</td>
<td>m-AUC</td>
<td>79.85</td>
<td>77.46</td>
<td>79.11</td>
<td>81.62</td>
<td>82.08</td>
<td>82.82</td>
</tr>
<tr>
<td></td>
<td>M-AUC</td>
<td>74.77</td>
<td>73.78</td>
<td>75.25</td>
<td>77.60</td>
<td>78.36</td>
<td>79.35*</td>
</tr>
<tr>
<td></td>
<td>m-F1</td>
<td>17.21</td>
<td>16.37</td>
<td>16.08</td>
<td>17.04</td>
<td>18.37</td>
<td>20.47*</td>
</tr>
<tr>
<td></td>
<td>M-F1</td>
<td>18.40</td>
<td>15.87</td>
<td>14.96</td>
<td>18.66</td>
<td>17.72</td>
<td>19.83*</td>
</tr>
</tbody>
</table>

Table 4: The performance in the multi-label classification with graph-structured input (m-X: micro average of X; M-X: macro average). SVM and HWN work on fingerprint representation; GRU works on string representation of molecule known as SMILES; WL+BR and CLN work directly on graph representation. Bold indicates better values. (*) $p < 0.05$.  

Drug-target binding as graph reasoning

Reasoning is to deduce knowledge from previously acquired knowledge in response to a query (or a cues)

Can be formulated as Question-Answering or Graph-Graph interaction:

- **Knowledge base**: Binding targets (e.g., RNA/protein sequence, or 3D structures), as a graph
- **Query**: Drug (e.g., SMILES string, or molecular graph)
- **Answer**: Affinity, binding sites, modulating effects
Drug-drug, drug-target & protein-protein as graph-graph interaction


Inferring (bio) relations as **knowledge graph completion**


Drug design as **structured machine translation**, aka conditional generation

Can be formulated as structured machine translation:
- Inverse mapping of (knowledge base + binding properties) to (query) → One to many relationship.

Representing graph as string (e.g., SMILES), and use sequence VAEs or GANs.

**Graph VAE & GAN**
- Model nodes & interactions
- Model cliques

Sequences
- Iterative methods

Reinforcement learning
- Discrete objectives

Any combination of these + memory.
Drug design as reinforcement learning

Agenda

- Why bother?
- Vectors & Sets
- Sequences
- The futurist
- Graphs
What can DL do to genomics?

**Deep learning offerings**
- Function approximation
- Program approximation
- Program synthesis
- Deep density estimation
- Disentangling factors of variation
- Capturing data structures
- Generating realistic data (sequences)
- Question-answering
- Information extraction
- Knowledge graph construction and completion

**Genomic problems**
- GWAS, gene-disease mapping
- Binding site identification
- Function prediction
- Drug-target binding
- Drug design
- Structure prediction
- Sequence generation
- Functional genomics
- Optimizing sequences
- Organizing the (knowledge about) omics universe
Deep learning versus genomics

Neuron ↔ Nucleotide, amino acid (building bricks)
Neural networks ↔ Chemical/biological networks (the house)
Message passing ↔ Signalling (the communication)
Neural programs ↔ Proteins/RNAs (the operating machines)
Neural Turing machine ↔ DNA (data + instruction + control)
Neural universe ↔ Omics universe (the computational universe)
Learning over time ↔ Co-evolution (adaptation)
Super Neural Turing machine ↔ DNA + Evolution (data + program + adaption)

Living bodies as multiple programs interacting

- We need new (neural) capabilities:
  - Truly Turing machine: programs can be stored and called when needed.
  - Can solve BIG problem with many sub-modules.
    - \( \rightarrow \) Compositional
  - Can reason given existing structures and knowledge bases

Neural Stored-program Memory

Living in the future: AI for health care

We tend to overestimate the short-term and underestimate the long-term.

Bear in mind that anything beyond 5 years are nearly impossible to predict!

Let’s map Kai-Fu Lee’s vision:

- **Wave 1:** Internet data (PubMed, social media)
- **Wave 2:** Business data (EMR)
- **Wave 3:** Digitalize the physical world (Drugs)
- **Wave 4:** Full automation (Robot surgeons, GPs)

Some speculations (by me):

The team
We’re hiring
PhD & Postdocs
truyen.tran@deakin.edu.au

https://truyentrans.github.io/scholarship.html